Search

In Stock

Buy Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) Online

DISEASE INDICATIONS: Cystic Fibrosis

MANUFACTURER: Vertex Pharmaceuticals Incorporated

USAGE: Oral

MEDICINE APPROVED BY:

Food and Drug Administration (FDA)

 

Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

From $39,106.10

Clear
Compare

Trikafta is a revolutionary pharmaceutical medication used for the treatment of cystic fibrosis (CF), a genetic disorder that affects the respiratory and digestive systems. It is a combination therapy that includes three active ingredients: elexacaftor, tezacaftor, and ivacaftor. Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

Here is a detailed description of Trikafta:

Active Ingredients:

  1. Elexacaftor: Elexacaftor is a CFTR modulator medication that targets specific CFTR protein defects. It helps these proteins to function more effectively, improving the transport of salt and fluids in and out of cells. This leads to reduced mucus thickness and improved lung function.
  2. Tezacaftor: Tezacaftor is another CFTR modulator that complements the action of elexacaftor. It helps the CFTR protein move to the cell surface, where it can function properly. This enhances the regulation of salt and fluid flow and further reduces mucus buildup.
  3. Ivacaftor: Ivacaftor is a CFTR potentiator medication. It enhances the function of the CFTR protein that has reached the cell surface, increasing chloride ion transport and further improving airway hydration.

Indications:

Trikafta is indicated for the treatment of CF in patients who have specific genetic mutations that are responsive to this combination therapy. It has been shown to be particularly effective in patients with at least one copy of the F508del mutation, among others.

Dosage Forms:

Trikafta is available in the form of oral tablets, which are taken by mouth.

Usage:

The dosing and administration of Trikafta are determined by a healthcare provider and are based on the patient’s age, weight, and specific genetic mutations. It is generally taken as prescribed, typically once or twice daily with food to optimize absorption.

Benefits:

Trikafta offers the potential to transform the lives of individuals with CF by addressing the underlying genetic defects responsible for the disease. It has been shown to significantly improve lung function, reduce respiratory symptoms, and enhance overall quality of life. For many patients, it represents a groundbreaking advancement in CF treatment.

Precautions:

Patients must undergo genetic testing to identify the specific mutations that make them eligible for Trikafta treatment. It is crucial to use Trikafta as directed by a healthcare provider and to be aware of potential side effects and drug interactions.

Side Effects:

Common side effects of Trikafta may include headache, upper respiratory tract infection, abdominal pain, and diarrhea. Patients should discuss any side effects or concerns with their healthcare provider. Serious side effects are possible but less common.

In conclusion, Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) is a groundbreaking combination medication used to treat cystic fibrosis in individuals with specific responsive mutations. It addresses the underlying genetic defects to improve lung function, reduce respiratory symptoms, and significantly enhance the overall quality of life for many patients with CF. Patients should use it as directed by their healthcare provider and be aware of potential side effects and precautions associated with its use. Trikafta represents a major advancement in the treatment of cystic fibrosis and offers hope for improved outcomes for those affected by this condition.

Package

84 tablets (fixed-dose combination containing 50 mg elexacaftor, 25 mg tezacaftor and 37.50 mg ivacaftor; 75 mg ivacaftor), 84 tablets (fixed-dose combination containing 100 mg elexacaftor, 50 mg tezacaftor and 75 mg ivacaftor; 150 mg ivacaftor)

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Yupelri (revefenacin) Online

(0 Reviews)
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease MANUFACTURER: Theravance Biopharma USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Yupelri is a pharmaceutical medication used to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by difficulty breathing, coughing, and wheezing.

Buy Tezspire (tezepelumab-ekko) Online

$6,696.25
(0 Reviews)
DISEASE INDICATIONS: Asthma MANUFACTURER: Amgen / AstraZeneca AB USAGE: Subcutaneous MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Tezspire (tezepelumab-ekko) is a prescription medication that belongs to the drug class of monoclonal antibodies. It is used to treat severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. Tezspire is the first and only biologic approved for severe asthma without phenotypic or biomarker limitations.

Buy Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) Online

From $39,106.10
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals Incorporated USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

Buy Orkambi (lumacaftor/ivacaftor) Online

From $10,806.14
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) This medication is designed to address the underlying cause of CF in individuals who have two copies of the F508del mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which is a common genetic mutation associated with CF.

Buy Symdeko (tezacaftor / ivacaftor) Online

$39,418.95
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) , Symdeko is indicated for the treatment of patients with CF who have specific genetic mutations that are responsive to these medications. This combination therapy addresses the underlying cause of CF by improving the function of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, which is often dysfunctional in CF patients.

Buy Kalydeco (ivacaftor) Online

From $7,241.59
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Kalydeco (ivacaftor) is a medication prescribed for individuals with cystic fibrosis (CF) who are 4 months of age and older and possess at least one CF gene mutation that responds to Kalydeco treatment.

Buy Clenbuterol Harasawa Online

$102.85
(0 Reviews)
DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS) MANUFACTURER: Harasawa USAGE: Oral MEDICINE APPROVED BY: Pharmaceuticals and Medical Devices Agency (PMDA) Clenbuterol, a medication employed in the management of individuals afflicted with bronchial asthma, chronic bronchitis, emphysema, acute bronchitis, or stress urinary incontinence, has diverse applications in the medical field. Notably, physicians occasionally opt for Clenbuterol's off-label use in the treatment of patients grappling with ALS (Amyotrophic Lateral Sclerosis). It's worth mentioning that Clenbuterol was previously recognized by its brand name, TONIL (clenbuterol).

Back to Top
Product has been added to your cart